{"id":871989,"date":"2025-08-06T18:37:10","date_gmt":"2025-08-06T22:37:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-half-2025-financial-results-provides-business-update\/"},"modified":"2025-08-06T18:37:10","modified_gmt":"2025-08-06T22:37:10","slug":"catalyst-pharmaceuticals-reports-record-second-quarter-and-first-half-2025-financial-results-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-half-2025-financial-results-provides-business-update\/","title":{"rendered":"Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update"},"content":{"rendered":"
\n

\n Achieved Record Q2 2025 Total Revenues <\/em>
\n of $146.6 Million, an Increase of 19.4% Yo<\/em>
\n Y, Marking Another Quarter of Consecutive Growth<\/em>\n <\/p>\n

\n Reported Record First Half 2025 Total Revenues <\/em>
\n of $288.0 Million, an Increase of 30.2% <\/em>
\n Over Prior Year<\/em>\n <\/p>\n

\n Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand<\/em>\n <\/p>\n

\n FIRDAPSE\u00ae Q2 2025 Net Product Revenue <\/em>
\n of $84.8 Million, Up 9.7% YoY; First Half 2025 Net Product Revenue of $168.6 Million, a 16.9%<\/em>
\n Increase Over <\/em>
\n Prior Year, Underscoring Sustained Momentum and Confidence in Long-Term Growth <\/em>\n <\/p>\n

\n AGAMREE\u00ae Q2 2025 Net Product Revenue of<\/em>
\n $27.4 Million, Up 212.9% YoY; First Half 2025 Net Product Revenue of $49.4 Million, a 398.0%<\/em>
\n Increase Over Prior Year, Highlighting Continued Product<\/em>
\n Momentum<\/em>\n <\/p>\n

\n FYCOMPA\u00ae Q2 2025 Net Product Revenue of<\/em>
\n $34.3 Million<\/em>
\n ; Slight Decrease YoY Due to Generic Entry Following Loss of Exclusivity<\/em>\n <\/p>\n

\n Strong Cash Position of $652.8 Million and No Funded Debt at the End of Q2 2025<\/em>\n <\/p>\n

\n Conference Call and Webcast to be Held on August 7, 2025, at 8:30 AM ET<\/em>\n <\/p>\n

CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc.\u00a0(“Catalyst” or “Company”) (Nasdaq: CPRX), today reported record financial results for the second quarter and first half of 2025, and provided a business update.\u00a0\u00a0<\/p>\n

\u201cCatalyst\u2019s record performance reflects disciplined execution and sustained demand across our portfolio, highlighting the meaningful impact our therapies have for patients,\u201d said Richard J. Daly, president and chief executive officer of Catalyst. \u201cWith portfolio momentum, focused execution, and a disciplined approach to growth, we are well-positioned to achieve our 2025 guidance and remain confident in our ability to deliver value for patients, providers, and our stakeholders.\u201d<\/p>\n

As expected, second-quarter results reflect a one-time timing anomaly stemming from last year\u2019s industry-wide Change Health insurance claims processing disruption, which resulted in an increase in claims adjudications in Q2 2024. The underlying demand for FIRDAPSE remains strong despite this temporary impact. In the first half of 2025, FIRDAPSE net revenues grew 16.9% over the same period in 2024, demonstrating the strength and resilience of our business. FIRDAPSE remains firmly on its multi-quarter growth trajectory.<\/p>\n

AGAMREE extended its momentum with robust triple-digit growth of 212.9% over the second quarter 2024 and 398.0% for the first half of 2025, achieving record revenue driven by accelerating physician adoption and continued uptake following its mid-March 2024 launch. FYCOMPA also delivered a strong revenue contribution and demonstrated durability following first approval of a generic version of the tablets in late May.\u00a0<\/p>\n

\n Financial Highlights<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n For the Three Months Ended June 30, <\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
(In thousands, except per share data)<\/em><\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Product Revenue, Net<\/td>\n$<\/td>\n146,540<\/td>\n$<\/td>\n122,653<\/td>\n19.5<\/td>\n%<\/td>\n<\/tr>\n
FIRDAPSE Product Revenue, Net<\/td>\n$<\/td>\n84,845<\/td>\n$<\/td>\n77,372<\/td>\n9.7<\/td>\n%<\/td>\n<\/tr>\n
AGAMREE Product Revenue, Net<\/td>\n$<\/td>\n27,363<\/td>\n$<\/td>\n8,746<\/td>\n212.9<\/td>\n%<\/td>\n<\/tr>\n
FYCOMPA Product Revenue, Net<\/td>\n$<\/td>\n34,332<\/td>\n$<\/td>\n36,535<\/td>\n(6.0<\/td>\n%)<\/td>\n<\/tr>\n
\n

GAAP Net Income<\/td>\n

$<\/td>\n52,108<\/td>\n$<\/td>\n40,794<\/td>\n27.7<\/td>\n%<\/td>\n<\/tr>\n
Non-GAAP Net Income *<\/td>\n$<\/td>\n86,350<\/td>\n$<\/td>\n69,631<\/td>\n24.0<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
GAAP Net Income Per Share – Basic<\/td>\n$<\/td>\n0.43<\/td>\n$<\/td>\n0.35<\/td>\n22.9<\/td>\n%<\/td>\n<\/tr>\n
Non-GAAP Net Income Per Share \u2013 Basic*<\/td>\n$<\/td>\n0.71<\/td>\n$<\/td>\n0.59<\/td>\n20.3<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
GAAP Net Income Per Share \u2013 Diluted<\/td>\n$<\/td>\n0.41<\/td>\n$<\/td>\n0.33<\/td>\n24.2<\/td>\n%<\/td>\n<\/tr>\n
Non-GAAP Net Income Per Share \u2013 Diluted*<\/td>\n$<\/td>\n0.68<\/td>\n$<\/td>\n0.56<\/td>\n21.4<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n As of June 30, 2025, and December 31, 2024<\/strong>
\n
\n (In thousands)<\/em>
\n
Cash and Cash Equivalents<\/td>\n		\n

$<\/td>\n

\n

\u00a0\u00a0 \u00a0\u00a0\u00a0 652,800<\/td>\n

\n

$<\/td>\n

\n

\u00a0\u00a0\u00a0 \u00a0\u00a0 517,553<\/td>\n

\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 26.1<\/td>\n

\n

%<\/td>\n<\/tr>\n<\/table>\n

\n
*Statements made in this press release include non-GAAP financial measures. Such information is provided as additional information and not as an alternative to Catalyst’s financial statements presented in accordance with U.S.\u00a0generally accepted accounting principles (“GAAP”). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst’s current financial performance. Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst’s operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting. Further, non-GAAP measures of net income used by Catalyst may be different from and not directly comparable to similarly titled measures used by other companies. <\/em><\/p>\n

\n Second Quarter and First Half 2025 Financial Highlights<\/strong>
\n
The Company delivered another record performance in the second quarter and the first half of 2025, driven by disciplined commercial execution, sustained portfolio demand, and the ongoing strength of the Company\u2019s long-term growth strategy.<\/p>\n